Sungen Biomedical and Taizhou People's Hospital Officially Signed a Contract for Integration and Development

On January 3, 2024, Taizhou People's Hospital Affiliated to Nanjing Medical University held a conference on "Integrated Development of Hospital and Enterprise - Innovation and Transformation". Zhu Li, Party Secretary of Taizhou People's Hospital Affiliated to Nanjing Medical University, President Chen Minglong, Vice President Chu Ming, as well as leaders of relevant government departments, and representatives of pharmaceutical enterprises and scientific research institutions attended the meeting.

At the meeting, Beijing Sungen Biomedical Technology Co., LTD. and Taizhou People's Hospital affiliated to Nanjing Medical University held a signing ceremony on "Research and development of innovative antibody drugs for cardiovascular diseases". At the same time, Professor Sun Zhiwei, General manager of Beijing Sungen Biomedical Technology Co., LTD. was appointed as "industry expert".

The collaboration with Taizhou People's Hospital further enriches Sungen's R&D pipeline and is of great significance for speeding up the R&D process.

Sungen Biomedical insists on developing First in class innovative drug to meet the unmet clinical needs and benefit human health.